long-term Survival In Light-chain Myeloma With Dialysis Therapy Alone
Australian and New Zealand Journal of Medicine 14(5): Oct 1984; 676-677
View Original Source →Case Details
Personal Characteristics
59-year-old woman
Clinical Characteristics
Presented in end-stage renal failure with stage iii b lambda light-chain myeloma (llcm), large tumour burden
Remission Characteristics
Considerable hematological improvement
Treatment & Mechanisms
Proposed Remission Mechanisms
Not discussed
Clinical Treatment
Continuous ambulatory peritoneal dialysis (capd)
Additional Notes
Despite a large tumour burden and refusal to accept cytotoxic chemotherapy, she was started on continuous ambulatory peritoneal dialysis (CAPD). With dialysis therapy alone she has shown considerable hematological improvement and remains well 18 months after diagnosis. The extremely poor prognosis attributed to light-chain myeloma is largely due to death from uremia. As the natural history of this disease in patients offered dialysis therapy is unknown, dialysis should not automatically be withheld from patients with LLCM.